Chronic lymphocytic leukaemia trials in China

In China 48 Also abroad 308

48 trials · From ClinicalTrials.gov, checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
Where
Bengbu, Changsha, Guangzhou, Shanghai, Tianjin, Wuhan, Zhanjiang, Zhengzhou
Age
18 years and over
People
344 worldwide
Run by
Ascentage Pharma Group Inc.
See details and how to joinNCT06319456 · EU 2024-514084-26-00
Early phase 1Taking people
A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
Where
Tianjin, Zhengzhou
Age
18 years to 75 years
People
28
Run by
Grit Biotechnology
See details and how to joinNCT07205315
Phase 2Not yet taking people in China
Zanubrutinib Induction Followed by Delayed Fixed-Duration Combination With Sonrotoclax for CLL/SLL：Stop Trial 2.0
Where
Changsha, Jinan, Nanchang, Nanjing, Shenzhen, Tianjin, Zhengzhou
Age
18 years and over
People
60
Run by
Yi Shuhua
See details and how to joinNCT07682415
Phase 2Taking people
A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Naïve, High-Risk CLL/SLL Patients
Where
Nanjing
Age
18 years to 75 years
People
24
Run by
The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT07671378
Phase 2Taking people
A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
Where
Beijing, Changchun, Changsha, Changzhou, Chengdu, Guangzhou, Hangzhou, Hefei, Nanchang, Nantong, Shenyang, Wuhan, Yichang, Zhengzhou
Age
18 years and over
People
66
Run by
Dizal Pharmaceuticals
See details and how to joinNCT07154264
Phase 3Taking people
Global Trial in APG2575 for Patients With CLL/SLL
Where
Beijing, Binzhou, Chenzhou, Foshan, Fuzhou, Guangzhou, Hefei, Luzhou, Nanchang, Nanjing, Nanning, Suzhou, Taiyuan, Wuhan, Wuxi, Xi'an, Yibin, Zhengzhou
Age
18 years to 99 years
People
400 worldwide
Run by
Ascentage Pharma Group Inc.
See details and how to joinNCT06104566 · EU 2023-508005-24-00
Phase 3Taking people
A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
Where
Nanjing, Tianjin
Age
18 years and over
People
250 worldwide
Run by
Dizal Pharmaceuticals
See details and how to joinNCT07139873 · EU 2025-522669-32-00
Phase 2Taking people
DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)
Where
Beijing, Changchun, Dalian, Guangzhou, Hefei, Jinan, Linyi, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Zhengzhou
Age
18 years and over
People
155
Run by
Dizal Pharmaceuticals
See details and how to joinNCT06539182
Phase 1Not yet taking people in China
U96-CAR-T-Cells For R/R B-ALL
Where
Suzhou
Age
18 years and over
People
30
Run by
The First Affiliated Hospital of Soochow University
See details and how to joinNCT07511426
Phase 2Taking people
Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
Where
Guangzhou, Haikou, Hanzhou, Nanchang, Suzhou, Tianjin, Wuhan, Zhengzhou
Age
18 years and over
People
75
Run by
Ascentage Pharma Group Inc.
See details and how to joinNCT05147467
No phaseNot yet taking people in China
A Study to Evaluate MTM-H-001 Injection in Adult Participants With Relapsed or Refractory B-cell Malignancies
Where
Langfang
Age
18 years to 75 years
People
69
Run by
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07476378
Early phase 1Taking people
Clinical Study on the Safety and Efficacy of BiTE-EV in Relapsed/Refractory Acute B-Cell Leukemia
Where
Beijing
Age
18 years to 70 years
People
3
Run by
Beijing GoBroad Hospital
See details and how to joinNCT06890494
Phase 2Taking people
Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy
Where
Nanjing
Age
18 years to 80 years
People
79
Run by
The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT06958705
Phase 2/3Taking people
ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
Where
Beijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Huai'an, Jinan, Jining, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Nanyang, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tangshan, Tianjin, Ürümqi, Wuhan, Xiamen, Xi'an, Yibin, Yichang, Zhengzhou, Zhenzhou, Zunyi
Age
18 years to 80 years
People
226
Run by
Beijing InnoCare Pharma Tech Co., Ltd.
See details and how to joinNCT06378138
Phase 1Taking people
Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies
Where
Tianjin
Age
18 years and over
People
44
Run by
CytoCares Inc
See details and how to joinNCT06037018
Phase 2Not yet taking people in China
Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study
Where
Changchun
Age
18 years and over
People
30
Run by
The First Hospital of Jilin University
See details and how to joinNCT07003464
No phaseTaking people
Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma
Where
Hefei
Age
3 years and over
People
18
Run by
Anhui Provincial Hospital
See details and how to joinNCT06961669
Phase 1/2Taking people
Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
Where
Beijing, Changsha, Chongqing, Guangzhou, Guiyang, Hangzhou, Nanchang, Nanjing, Nanning, Shanghai, Shijiazhuang, Suzhou, Tianjin, Wuhan, Zhenzhou
Age
18 years and over
People
123
Run by
Ascentage Pharma Group Inc.
See details and how to joinNCT04494503
No phaseNot yet taking people in China
JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Leukemia
Where
Hangzhou
Age
18 years to 75 years
People
24
Run by
He Huang
See details and how to joinNCT06902025
Phase 1/2Taking people
CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma
Where
Beijing
Age
14 years to 75 years
People
20
Run by
Affiliated Hospital to Academy of Military Medical Sciences
See details and how to joinNCT06834529
Early phase 1Taking people
CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL
Where
Hangzhou
Age
18 years and over
People
20
Run by
Zhejiang University
See details and how to joinNCT06346912
No phaseTaking people
CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+
Where
Tianjin
Age
3 years to 18 years
People
60
Run by
Zhu Xiaofan
See details and how to joinNCT06355739
Phase 2Taking people
A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL
Where
Tianjin
Age
18 years to 75 years
People
50
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT03980002